ストックスクリーナーアプリを入手
16.69
3.19%
-0.55
アフターアワーズ：
16.66
-0.03
-0.18%
前日終値:
$17.24
開ける：
$17.52
24時間の取引高:
33.36M
Relative Volume:
1.58
時価総額：
$3.80B
収益：
$1.78B
当期純損益:
$164.40M
株価収益率:
24.19
EPS:
0.69
ネットキャッシュフロー:
$236.51M
1週間 パフォーマンス:
-31.60%
1か月 パフォーマンス:
-47.33%
6か月 パフォーマンス:
-66.61%
1年 パフォーマンス:
-61.70%
1日の値動き範囲:
$16.60
$17.63
1週間の範囲:
$16.35
$27.77
52週間の値動き範囲:
$16.35
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
16.69 | 3.92B | 1.78B | 164.40M | 236.51M | 0.69 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-12 | 開始されました | Evercore ISI | In-line |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-10-21 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Hims & Hers Pulls Wegovy Pill Dupe After FDA Threats — Novo Nordisk Files Patent Lawsuit Anyway - Everyday Health
Novo to Follow Lilly and Sell Obesity Shot Wegovy in Vials - Bloomberg.com
Hims & Hers Faces Legal and Regulatory Headwinds, Stock Plummets - StocksToTrade
HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In? - Stocktwits
HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell? - The Globe and Mail
Hims & Hers: Does Big Pharma Always Win? (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha
HIMS Selloff Creates De-Risked Entry (NYSE:HIMS) - Seeking Alpha
Hims & Hers Halts Compounded Semaglutide Pill Offering After FDA's Crackdown Warning - AOL.com
Pharmaceutical industry spends more on ads in the US despite stricter FDA guidelines - medwatch.com
The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 46% - simplywall.st
Novo’s GLP-1 Patent Suit Against Hims Takes Aim at Compounding - Bloomberg Law News
Hims is in the crosshairs. Is a crackdown coming for compounding? - statnews.com
Deutsche Bank Maintains Hold on HIMS (Hims & Hers) Feb 10, 2026 - Meyka
'Health risk': Novo Nordisk sues Hims & Hers over cheaper version of Ozempic, Wegovy fat loss pills - MSN
Meet The Attys For Novo Nordisk In Hims & Hers GLP-1 Row - Law360
Legal pressures mount for Hims & Hers over GLP-1 sales - The Hill
Novo Nordisk Takes On Hims Over Copycat GLP-1 Pill - Law360
Stocks making big moves yesterday: Shopify, Snowflake, Ryan Specialty, Merchants Bancorp, and Hims & Hers Health - The Globe and Mail
Novo Nordisk Files Patent Lawsuit Against Hims & Hers Over Compounded Semaglutide Products - Law Commentary
Fight over GLP-1 alternatives escalates as Novo Nordisk sues Hims & Hers - Axios
Novo Nordisk sues Hims & Hers over ‘knock-off Wegovy’ - The Hill
Decoding Hims & Hers Health's Options Activity: What's the Big Picture? - Benzinga
Palmetto Grain Brokerage - Palmetto Grain Brokerage
As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock? - Yahoo Finance
Hims & Hers Health: The GLP-1 Trade Just Got Real (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha
The Vertical Integration of Wellness: A Deep Dive into Hims & Hers Health (HIMS) - FinancialContent
Deutsche Bank Cuts Price Target on Hims & Hers Health to $31 From $42, Keeps Hold Rating - marketscreener.com
Hims & Hers Health Stock (HIMS) Opinions on Novo Nordisk Lawsuit - Quiver Quantitative
Novo Nordisk, maker of Ozempic, sues over weight loss drug copycats - NewsNation
Hims & Hers says Novo Nordisk lawsuit ‘blatant attack’ on millions of Americans - Yahoo Finance
Hims & Hers Health, Inc. $HIMS Shares Purchased by Candriam S.C.A. - MarketBeat
Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny - TechStock²
Hims And Hers Retreats On GLP1 Pills As Legal And Regulatory Risks Grow - Yahoo Finance
Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded Semaglutide - Yahoo Finance Singapore
The Knockoff GLP-1 Market Is Still the Wild West - Bloomberg.com
Hims & Hers retreats from compounded GLP-1 pill - Axios
Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies - Yahoo Finance
Why Hims Stock Slid 40% In A Month? - Forbes
Hims built a boundary-pushing health business. Now the legal risks are catching up. - Sherwood News
Hims and Novo Nordisk: Compounded Oral Semaglutide Pulled After Legal Challenge and HHS Pressure - Morningstar Canada
Hims & Hers Stock (-16%): GLP-1 Ambitions Crushed by Lawsuit & FDA - Trefis
‘Blatant Attack’: HIMS Stock Plunges as Novo Lawsuit Triggers Analyst Price Target Cuts - TipRanks
Novo Nordisk Launches Suit to Knock Out Hims & Hers’ Weight Loss Knockoffs - Yahoo Finance
Hims Pulls Cheaper Wegovy Pill After Federal Scrutiny - Optometry Advisor
Stocks to Watch Monday Recap: Novo Nordisk, Hims & Hers, Apollo - The Wall Street Journal
Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit - Yahoo Finance
Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit - The Motley Fool
Novo Nordisk going forward with suit against Hims & Hers despite it scrapping plans to sell copycat Wegovy pill - The Boston Globe
Hims & Hers Health: Don’t Fall For The Hysteria (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Novo Nordisk sues hims & hers over Ozempic, Wegovy knockoffs - cbsnews.com
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
0.15%
大文字化:
|
ボリューム (24 時間):